Indication
Stage I
7 clinical trials
7 products
3 drugs
Clinical trial
A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood PressureStatus: Completed, Estimated PCD: 2017-04-25
Product
VehicleProduct
B244Clinical trial
A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153Status: Recruiting, Estimated PCD: 2025-04-01
Product
PembrolizumabClinical trial
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2024-07-01
Drug
AN0025Clinical trial
A Phase II Study of Circulating Tumor DNA Directed Consolidation Durvalumab (MEDI4736) Following Induction and Concurrent Durvalumab With SABR for Stage I NSCLC. SCION: SABR and Checkpoint Inhibition Of NSCLCStatus: Recruiting, Estimated PCD: 2026-12-01
Product
DurvalumabClinical trial
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell CarcinomaStatus: Recruiting, Estimated PCD: 2027-04-01
Product
AvelumabDrug
VarlilumabClinical trial
Predicting Esophageal Cancer Borders Using PET-Imaging PEGASUSStatus: Recruiting, Estimated PCD: 2026-01-01
Drug
DocetaxelClinical trial
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological ResponseStatus: Recruiting, Estimated PCD: 2025-03-01
Product
NivolumabProduct
Relatlimab